Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
AstraZeneca
Moodys
Baxter
Mallinckrodt

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR ONGLYZA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Onglyza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00575588 ↗ 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period Completed Bristol-Myers Squibb Phase 3 2007-12-01 Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.
NCT00575588 ↗ 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period Completed AstraZeneca Phase 3 2007-12-01 Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.
NCT00614939 ↗ Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment Completed Bristol-Myers Squibb Phase 3 2008-01-01 Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Onglyza

Condition Name

Condition Name for Onglyza
Intervention Trials
Type 2 Diabetes 21
Type 2 Diabetes Mellitus 18
Diabetes Mellitus, Type 2 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Onglyza
Intervention Trials
Diabetes Mellitus, Type 2 51
Diabetes Mellitus 48
Glucose Intolerance 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Onglyza

Trials by Country

Trials by Country for Onglyza
Location Trials
United States 211
China 58
United Kingdom 31
Canada 29
India 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Onglyza
Location Trials
Texas 18
California 12
Florida 10
Ohio 10
Georgia 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Onglyza

Clinical Trial Phase

Clinical Trial Phase for Onglyza
Clinical Trial Phase Trials
Phase 4 25
Phase 3 20
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Onglyza
Clinical Trial Phase Trials
Completed 49
Unknown status 11
Recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Onglyza

Sponsor Name

Sponsor Name for Onglyza
Sponsor Trials
AstraZeneca 40
Bristol-Myers Squibb 14
The University of Texas Health Science Center at San Antonio 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Onglyza
Sponsor Trials
Industry 55
Other 46
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Moodys
Mallinckrodt
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.